OncoGenex announces publication of OGX-427 pre-clinical data OncoGenex Pharmaceuticals announced that pre-clinical data evaluating its investigational compound, OGX-427, in pancreatic cancer was published online in Cell Death and Disease. OGX-427 is designed to reduce levels of heat shock protein 27, or Hsp27, a protein that is highly expressed in many types of cancer. Overexpression of Hsp27 is believed to be an important factor leading to the development of treatment resistance and is associated with negative clinical outcomes in various tumor types. As reported by the authors, OGX-427 data in pancreatic cancer are consistent with previously published studies in bladder, prostate and lung cancers, where expression of Hsp27 was correlated wi th the promotion of tumor cell growth and treatment resistance. In addition, the study demonstrated that treatment with OGX-427 monotherapy decreased levels of Hsp27 in tumor cells and reduced tumor volume by approximately 50 percent. Importantly, when OGX-427 was added to gemcitabine, a commonly used chemotherapy in pancreatic and other cancers, greater decreases in tumor volume, when compared to gemcitabine alone, were reported. :theflyonthewall.com
Looking forward to the Q3 CC next week. They'll probably talk about this and about the initiation of the P2 trial for 427 in bladder. I'm hoping they'll provide an update on enrollment in the SATURN trial for 011, now that the FDA has approved expansion of the enrollment criteria. Also hoping they'll provide an update on the plans they and Teva have for initiation of the P3 trial in lung for 011. Cormack said at one of the recent investor conferences that they were planning to meet with Teva on that so maybe they made some progress.